{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04965636",
            "orgStudyIdInfo": {
                "id": "215360"
            },
            "organization": {
                "fullName": "GlaxoSmithKline",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)",
            "officialTitle": "A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome",
            "acronym": "SPHERE",
            "therapeuticArea": [
                "Rare Diseases"
            ],
            "study": "study-in-pediatrics-with-hypereosinophilic-syndrome-sphere"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": true,
                "nctId": "NCT00244686",
                "statusForNctId": "NO_LONGER_AVAILABLE"
            },
            "startDateStruct": {
                "date": "2022-08-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-16",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-09-16",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-07-07",
            "studyFirstSubmitQcDate": "2021-07-07",
            "studyFirstPostDateStruct": {
                "date": "2021-07-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-08",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "GlaxoSmithKline",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy."
        },
        "conditionsModule": {
            "conditions": [
                "Hypereosinophilic Syndrome"
            ],
            "keywords": [
                "Hypereosinophilic Syndrome",
                "Mepolizumab",
                "Safety",
                "Efficacy",
                "Pediatric",
                "Adolescent"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "This is a single arm study",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "This is an open-label study"
                }
            },
            "enrollmentInfo": {
                "count": 25,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Participants receiving mepolizumab",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Mepolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Mepolizumab",
                    "description": "Mepolizumab will be provided in pre-filled safety syringe",
                    "armGroupLabels": [
                        "Participants receiving mepolizumab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of HES flares experienced by participants per year",
                    "description": "The annualized rate of HES flares will be measured.",
                    "timeFrame": "Up to Week 52"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in mean daily oral corticosteroids (OCS) dose (prednisone/prednisolone or equivalent) from Weeks 0 to 4 to Weeks 48 to 52",
                    "description": "Change in mean daily OCS dose (prednisone/prednisolone or equivalent) will be assessed.",
                    "timeFrame": "Weeks 0 to 4 and Weeks 48 to 52"
                },
                {
                    "measure": "Number of participants with >=50 percent (%) reduction in mean daily OCS dose (prednisone/prednisolone or equivalent) from Weeks 0 to 4 compared with Weeks 48 to 52",
                    "description": "Number of participants with \\>=50% reduction in mean daily OCS dose (prednisone/prednisolone or equivalent) will be assessed.",
                    "timeFrame": "Weeks 0 to 4 and Weeks 48 to 52"
                },
                {
                    "measure": "Number of participants achieving a mean daily OCS dose (prednisone/prednisolone or equivalent) of <=7.5 milligrams (mg) during Weeks 48 to 52 in participants that are taking OCS at Baseline",
                    "description": "Number of participants achieving a mean daily OCS dose (prednisone/prednisolone or equivalent) of \\<=7.5 mg will be assessed.",
                    "timeFrame": "Weeks 48 to 52"
                },
                {
                    "measure": "Number of participants achieving a mean daily OCS dose (prednisone/prednisolone or equivalent) of <=7.5 mg during Weeks 48 to 52",
                    "description": "Participants achieving mean daily OCS dose (prednisone/prednisolone or equivalent) of \\<=7.5 mg will be evaluated.",
                    "timeFrame": "Weeks 48 to 52"
                },
                {
                    "measure": "Change from Baseline in fatigue severity based on Brief Fatigue Inventory (BFI) Item 3 (worst level of fatigue during past 24 hours) for Week 52",
                    "description": "Item 3 of the BFI is a 11-point scale that measures fatigue (weariness, tiredness) ranging from 0 \"no fatigue\" to 10 \"as bad as you can imagine\".",
                    "timeFrame": "Baseline and up to Week 52"
                },
                {
                    "measure": "Number of participants with Anti-drug antibodies (ADA) and neutralizing antibodies (NAb)",
                    "description": "Participants with ADA and NAb will be evaluated.",
                    "timeFrame": "Up to Week 52"
                },
                {
                    "measure": "Ratio to Baseline in absolute blood eosinophil count",
                    "description": "Blood samples will be collected.",
                    "timeFrame": "Baseline and up to Week 52"
                },
                {
                    "measure": "Mepolizumab plasma concentrations",
                    "description": "Blood samples will be collected for determination of mepolizumab plasma concentration.",
                    "timeFrame": "Week 4 and up to Week 52"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be aged 6 to 17 years inclusive, at Screening (Visit 1).\n* Participants who have been diagnosed with HES for at least 6 months prior to enrolment (Visit 2).\n* A history of 2 or more HES flares within the past 12 months prior to Screening (Visit 1).\n* Participants must have blood eosinophil count \\>=1000 cells per microliter (/mcL) present at Screening.\n* Participants must be on a stable dose of HES therapy for the 4 weeks prior to the first dose of mepolizumab (Visit 2)\n* Male and/or female\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Life-threatening HES or life-threatening HES co-morbidities\n* Other concurrent medical conditions that may affect the participant's safety\n* Eosinophilia of unknown significance\n* Fusion tyrosine kinase gene translocation \\[FIP1L1- Platelet-derived Growth Factor Receptor (PDGFR\u03b1) (F/P)\\] positivity\n* Clinical diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA)\n* Participants with chronic or ongoing active infections requiring systemic treatment, as well as participants who have experienced clinically significant infections due to viruses, bacteria, and fungi within 4 weeks prior to enrolment (Visit 2)\n* Participants with a pre-existing parasitic infestation within 6 months prior to enrolment (Visit 2)\n* Participants with a known immunodeficiency (e.g. Human immunodeficiency virus \\[HIV\\]), other than that explained by the use of OCS or other therapy taken for HES\n* Participants with documented history of any clinically significant cardiac damage prior to Screening (Visit 1) that, in the opinion of the investigator, would impact the participant's participation during the study\n* Participants with a history of or current lymphoma, Participants with current malignancy or previous history of cancer in remission for less than 12 months prior to Screening (Visit 1)\n* Participants who are not responsive to OCS based on clinical response or blood eosinophil counts.\n* Participants who have previously received mepolizumab in the 4 months prior to enrolment (Visit 2)\n* Participants receiving non-oral systemic corticosteroids in the 4-week period prior to enrolment (Visit 2).\n* Participants who have received any other monoclonal antibodies within 30 days or 5 half-lives, whichever is longer, of enrolment (Visit 2).\n* Participants who have received treatment with an investigational agent (biologic or non-biologic) within the past 30 days or 5 drug half-lives, whichever is longer, prior to enrolment (Visit 2).\n* Use of candidate Coronavirus disease 2019 (COVID-19) vaccines that have not received limited, accelerated, or full authorization/approval, and are only in use as part of a clinical trial.\n* Participants who are currently participating in any other interventional clinical study\n* Participants with any history of hypersensitivity to any monoclonal antibody (including mepolizumab).\n* Evidence of clinically significant abnormality in the hematological, biochemical, or urinalysis screen from the sample collected at Screening (Visit 1), that could put the participant's safety at risk by participating in the study, as judged by the investigator",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Years",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "877-379-3718",
                    "email": "GSKClinicalSupportHD@gsk.com"
                },
                {
                    "name": "EU GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "+44 (0) 20 89904466",
                    "email": "GSKClinicalSupportHD@gsk.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "GSK Clinical Trials",
                    "affiliation": "GlaxoSmithKline",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Thanai Pongdee",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29425",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Caba",
                    "state": "Buenos Aires",
                    "zip": "C1028AAP",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Pablo Mat\u00edas Pascale",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Florencio Varela",
                    "state": "Buenos Aires",
                    "zip": "1888",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.82722,
                        "lon": -58.39556
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Florida",
                    "state": "Buenos Aires",
                    "zip": "1602",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ]
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Quilmes",
                    "state": "Buenos Aires",
                    "zip": "1878",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.72904,
                        "lon": -58.26374
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Sao Paulo",
                    "state": "S\u00e3o Paulo",
                    "zip": "05410-002",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Vicente Odone Filho",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Sorocaba",
                    "state": "S\u00e3o Paulo",
                    "zip": "18040-425",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": -23.50167,
                        "lon": -47.45806
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Petach Tikva",
                    "zip": "49202",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08707,
                        "lon": 34.88747
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Monterrey",
                    "state": "Nuevo Le\u00f3n",
                    "zip": "64060",
                    "country": "Mexico",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.67507,
                        "lon": -100.31847
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28009",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Ankara",
                    "zip": "6230",
                    "country": "Turkey",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Sule Unal",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.91987,
                        "lon": 32.85427
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Izmir",
                    "zip": "35100",
                    "country": "Turkey",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Yesim Aydinok",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.41273,
                        "lon": 27.13838
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Kayseri",
                    "zip": "38039",
                    "country": "Turkey",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.73222,
                        "lon": 35.48528
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "SE5 9RS",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "IPD for this study will be made available via the Clinical Study Data Request site.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.",
            "accessCriteria": "Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",
            "url": "http://clinicalstudydatarequest.com"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017681",
                    "term": "Hypereosinophilic Syndrome"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000004802",
                    "term": "Eosinophilia"
                },
                {
                    "id": "D000007960",
                    "term": "Leukocyte Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19901",
                    "name": "Hypereosinophilic Syndrome",
                    "asFound": "Hypereosinophilic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7961",
                    "name": "Eosinophilia",
                    "relevance": "LOW"
                },
                {
                    "id": "M10963",
                    "name": "Leukocyte Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T2886",
                    "name": "Hypereosinophilic Syndrome",
                    "asFound": "Hypereosinophilic Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}